Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > 10X
View:
Post by wj on Mar 31, 2022 11:18am

10X

It sounds like you are long-holding investor who has been incredibly patient yet has time-sensitivity needs relating to your SVA position.  I get it.
I share some of your frustrations, yet, to be honest,  the Biotechs I have done well in have always taken more time to monetize.   I am not sure what your ACB is, but assuming it was around 2+ years ago when you started to build a position, you are likely already up 10x.   Very few other sectors would have compared to this uptick.    I also have discovered, through other investments I have made in the biotech sector,  the longer a deal takes to paper, likely will have accretive benefits to the long holding investor.  Management is versed in deal-making, licencing, legal and an external NY group is working on this too.  Keep in mind this is a relatively newly-minted space (regen med), and science, rights of use, M&A implications, all of this this often takes more time to hammer out.   I do share some of your fatigue.   But I sense this will all be worth it.   At this stage,  I know ‘quiet is good’.   Thank you for your post.   I am adding at these levels, but like you, are eager to see all of this cross the line.
Comment by Sailboatdream on Mar 31, 2022 4:57pm
I have to disagree here.  Annualized returns since Philip joined are not 10x.  And all of this share price increase happened since Dec 2020.  With Jan 2021 share price reaching close to $3.  Today we are back to low $1.40's.   With stagnation most of the year.  Except specific periods, such as Nov 2021 and Jan 2022 where there were clear expectations of a deal ...more  
Comment by Stockfshr on Mar 31, 2022 6:38pm
Sailboat - Phil is building a company, not your portfolio.
Comment by Sailboatdream on Mar 31, 2022 7:39pm
Again, have to disagree.  He has built a series of successful clinal trials.  Hasn't made it into a company yet.  And not clear he is in the process of doing so successfully.  Plus, as a shareholder (and owner ) of the company, Phil's mandate is creating and preserving shareholder value.  He is not succeeding at this in my opinion.  Even Frank's help is ...more  
Comment by Metalsguy1 on Apr 01, 2022 1:37am
sailboatdream...you are right. Frank isn't helping but stockfshr is sure enjoying the mustache rides.
Comment by Metalsguy1 on Apr 01, 2022 1:34am
no he isn't building a company he is fleecing retail investors so that management can feather their nests with DSUs.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities